Skip to main content
. 2016 Sep 19;5(11):e1232220. doi: 10.1080/2162402X.2016.1232220

Figure 5.

Figure 5.

Promiscuous binding of BCR peptides to HLA DRB1 alleles. (A) IFNγ ELISA assay of allogeneic (normal donors) and (B) autologous CD4+ T cells stimulated with B lymphoblastoid cell lines (BLCLs), pulsed or nonpulsed with BCR peptides. (C) IFNγ ELISA assay of BCR framework region-specific CD4+ T cells stimulated with lymphoma expressing the same epitope and mismatched HLA DRB1 alleles. (D) Cytotoxicity (E/T ratio=10:1) of autologous BCR peptide-specific CD4+ T cells against lymphomas or tumor-free PBMCs expressing the same epitope and mismatched HLA DRB1 alleles. Data are representative of three individual experiments.